Table 1 Baseline demographic and clinical characteristics of patients with primary bladder sarcoma in the training cohort and validation cohort
Characteristics | Total cohort (n = 866) | Training cohort (n = 608) | Validation cohort (n = 258) | P-value |
|---|---|---|---|---|
Total | 866 | 608 | 258 | |
Age (IQR) | 73.0 (60.2, 81.0) | 73.0 (60.8, 81.0) | 73.0 (60.2, 81.8) | 0.963 |
Age, n (%) | 0.517 | |||
18–29 | 27 (3.1) | 21 (3.5) | 6 (2.3) | |
30–39 | 28 (3.2) | 22 (3.6) | 6 (2.3) | |
40–49 | 56 (6.5) | 33 (5.4) | 23 (8.9) | |
50–59 | 94 (10.9) | 67 (11) | 27 (10.5) | |
60–69 | 156 (18.0) | 109 (17.9) | 47 (18.2) | |
70–79 | 248 (28.6) | 176 (28.9) | 72 (27.9) | |
≥ 80 | 257 (29.7) | 180 (29.6) | 77 (29.8) | |
Sex, n (%) | 1.000 | |||
Female | 337 (38.9) | 237 (39) | 100 (38.8) | |
Male | 529 (61.1) | 371 (61) | 158 (61.2) | |
Race, n (%) | 0.189 | |||
White | 743 (85.8) | 530 (87.2) | 213 (82.6) | |
Black | 90 (10.4) | 58 (9.5) | 32 (12.4) | |
Other | 33 (3.8) | 20 (3.3) | 13 (5) | |
Marital status, n (%) | 0.381 | |||
Married | 484 (55.9) | 342 (56.2) | 142 (55) | |
Single | 353 (40.8) | 249 (41) | 104 (40.3) | |
Unknown | 29 (3.3) | 17 (2.8) | 12 (4.7) | |
Pathological classification, n (%) | 0.633 | |||
Carcinosarcoma | 408 (47.1) | 296 (48.7) | 112 (43.4) | |
Leiomyosarcoma | 207 (23.9) | 141 (23.2) | 66 (25.6) | |
Sarcoma | 84 (9.7) | 59 (9.7) | 25 (9.7) | |
Spindle cell sarcoma | 31 (3.6) | 22 (3.6) | 9 (3.5) | |
Other | 136 (15.7) | 90 (14.8) | 46 (17.8) | |
Histological grade, n (%) | 0.166 | |||
Well differentiated | 22 (2.5) | 16 (2.6) | 6 (2.3) | |
Moderately differentiated | 38 (4.4) | 29 (4.8) | 9 (3.5) | |
Poorly differentiated | 202 (23.3) | 151 (24.8) | 51 (19.8) | |
Undifferentiated | 283 (32.7) | 184 (30.3) | 99 (38.4) | |
Unknown | 321 (37.1) | 228 (37.5) | 93 (36) | |
T-stage, n (%) | 0.124 | |||
Ta | 68 (7.9) | 55 (9) | 13 (5) | |
Tis | 1 (0.1) | 1 (0.2) | 0 (0) | |
T1 | 68 (7.9) | 45 (7.4) | 23 (8.9) | |
T2 | 94 (10.9) | 63 (10.4) | 31 (12) | |
T3 | 92 (10.6) | 72 (11.8) | 20 (7.8) | |
T4 | 54 (6.2) | 40 (6.6) | 14 (5.4) | |
Unknown | 489 (56.5) | 332 (54.6) | 157 (60.9) | |
N-stage, n (%) | 0.286 | |||
No | 476 (55.0) | 329 (54.1) | 147 (57) | |
Yes | 175 (20.2) | 119 (19.6) | 56 (21.7) | |
Unknown | 215 (24.8) | 160 (26.3) | 55 (21.3) | |
M-stage, n (%) | 0.326 | |||
No | 593 (68.5) | 407 (66.9) | 186 (72.1) | |
Yes | 97 (11.2) | 71 (11.7) | 26 (10.1) | |
Unknown | 176 (20.3) | 130 (21.4) | 46 (17.8) | |
Tumor size, n (%) | 0.622 | |||
< 4.8 | 161 (18.6) | 117 (19.2) | 44 (17.1) | |
≥ 4.8 | 291 (33.6) | 199 (32.7) | 92 (35.7) | |
Unknown | 414 (47.8) | 292 (48) | 122 (47.3) | |
Surgical treatment, n (%) | 0.023* | |||
No | 54 (6.2) | 38 (6.2) | 16 (6.2) | |
Yes | 537 (62.0) | 360 (59.2) | 177 (68.6) | |
Unknown | 275 (31.8) | 210 (34.5) | 65 (25.2) | |
Radiation | 0.360 | |||
No/Unknown, n (%) | 754 (87.1) | 534 (87.8) | 220 (85.3) | |
Yes | 112 (12.9) | 74 (12.2) | 38 (14.7) | |
Chemotherapy, n (%) | 0.864 | |||
No/Unknown | 734 (84.8) | 514 (84.5) | 220 (85.3) | |
Yes | 132 (15.2) | 94 (15.5) | 38 (14.7) |